Old Web
English
Sign In
Acemap
>
authorDetail
>
Dickson C
Dickson C
Eli Lilly and Company
Placebo
Lupus erythematosus
Physical therapy
Tabalumab
Medicine
3
Papers
153
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
2016
Annals of the Rheumatic Diseases
Joan T. Merrill
van, Vollenhoven, Rf
Jill P. Buyon
Richard Furie
William Stohl
Ma Morgan-Cox
Dickson C
Anderson Pw
Chin Lee
Pierre-Yves Berclaz
Thomas Dörner
Show All
Source
Cite
Save
Citations (143)
EFFICACY AND SAFETY OF TABALUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM 2 PHASE 3, 52-WEEK, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIALS
2015
D. Isenberg
Joan T. Merrill
Robert W Hoffman
Matthew D. Linnik
Ma Morgan-Cox
Melissa Veenhuizen
N Iikuni
Dickson C
Maria E Silk
Daniel J. Wallace
T. Doerner
Show All
Source
Cite
Save
Citations (1)
OP0184 Efficacy and Safety of Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Placebo-Controlled Trials
2015
Annals of the Rheumatic Diseases
D. Isenberg
Joan T. Merrill
Robert W Hoffman
Matthew D. Linnik
Ma Morgan-Cox
Melissa Veenhuizen
N Iikuni
Dickson C
Maria E Silk
Daniel J. Wallace
Thomas Dörner
Show All
Source
Cite
Save
Citations (9)
1